Aspirin works by thinning the blood so that clots are less likely to form and block blood flow to the heart or brain. This simple medicine has saved many lives and is still commonly recommended by ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

Compared with those assigned to aspirin, patients assigned to a P2Y12 inhibitor had a lower net composite of adverse cardiac and cerebrovascular events. HealthDay News — For patients who undergo ...

Please provide your email address to receive an email when new articles are posted on . P2Y12 monotherapy after PCI was not as protective from ischemic events vs. DAPT with aspirin. Monotherapy did ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

NEW ORLEANS — Two new studies from Asia provide more evidence that extended monotherapy with clopidogrel (Plavix, Sanofi) or another P2Y12 inhibitor antiplatelet, rather than either dual antiplatelet ...

Madrid, Spain – 31 August 2025: Noninferiority was not demonstrated for death and ischaemic events between P2Y12 inhibitor monotherapy and dual antiplatelet therapy (DAPT) given for 12 months after ...

Two new Asian studies have shown that short durations of dual antiplatelet therapy (DAPT) followed by longer treatment with P2Y12 inhibitor monotherapy alone may be a safe and effective regimen for ...

Noninferiority was not demonstrated for death and ischemic events between P2Y12 inhibitor monotherapy and dual antiplatelet therapy (DAPT) given for 12 months after stenting in patients with acute ...

Patients with atrial fibrillation (AF) who’ve recently experienced an acute coronary syndrome or undergone PCI are best served by an antithrombotic strategy that includes a P2Y12 inhibitor and a ...

In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention ...